Sector Gamma AS Has $9.89 Million Position in Catalent, Inc. (NYSE:CTLT)

Sector Gamma AS grew its holdings in Catalent, Inc. (NYSE:CTLT) by 173.6% during the 1st quarter, HoldingsChannel reports. The firm owned 150,501 shares of the company’s stock after purchasing an additional 95,501 shares during the quarter. Catalent comprises approximately 2.4% of Sector Gamma AS’s holdings, making the stock its 15th largest position. Sector Gamma AS’s holdings in Catalent were worth $9,889,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Dimensional Fund Advisors LP increased its stake in shares of Catalent by 1.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,127,337 shares of the company’s stock valued at $74,072,000 after purchasing an additional 16,416 shares during the last quarter. Blair William & Co. IL boosted its holdings in shares of Catalent by 199.5% during the 1st quarter. Blair William & Co. IL now owns 100,074 shares of the company’s stock valued at $6,576,000 after acquiring an additional 66,658 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S boosted its holdings in shares of Catalent by 163.5% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 809 shares of the company’s stock valued at $53,000 after acquiring an additional 502 shares in the last quarter. First Republic Investment Management Inc. boosted its holdings in shares of Catalent by 171.7% during the 1st quarter. First Republic Investment Management Inc. now owns 104,348 shares of the company’s stock valued at $6,857,000 after acquiring an additional 65,940 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Catalent by 16.5% during the 1st quarter. ProShare Advisors LLC now owns 28,363 shares of the company’s stock valued at $1,864,000 after acquiring an additional 4,013 shares in the last quarter.

Catalent Trading Up 2.0 %

NYSE:CTLT traded up $0.99 during mid-day trading on Thursday, hitting $49.97. 2,490,469 shares of the stock traded hands, compared to its average volume of 3,465,541. The stock has a market capitalization of $9.01 billion, a price-to-earnings ratio of 227.78, a PEG ratio of 5.96 and a beta of 1.23. Catalent, Inc. has a 52 week low of $31.45 and a 52 week high of $99.50. The firm’s 50 day moving average is $45.65 and its two-hundred day moving average is $50.67. The company has a quick ratio of 1.34, a current ratio of 1.84 and a debt-to-equity ratio of 0.91.

Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, August 29th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Catalent had a return on equity of 7.13% and a net margin of 0.93%. The business’s revenue was down 15.6% compared to the same quarter last year. During the same period last year, the business posted $1.12 earnings per share. On average, equities research analysts predict that Catalent, Inc. will post 0.83 earnings per share for the current year.

Insider Buying and Selling at Catalent

In other Catalent news, CEO Alessandro Maselli sold 1,485 shares of Catalent stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $47.13, for a total value of $69,988.05. Following the completion of the transaction, the chief executive officer now owns 86,101 shares of the company’s stock, valued at $4,057,940.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Steven L. Fasman sold 817 shares of the company’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $44.65, for a total value of $36,479.05. Following the completion of the transaction, the executive vice president now owns 73,789 shares in the company, valued at approximately $3,294,678.85. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Alessandro Maselli sold 1,485 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $47.13, for a total transaction of $69,988.05. Following the completion of the transaction, the chief executive officer now owns 86,101 shares of the company’s stock, valued at approximately $4,057,940.13. The disclosure for this sale can be found here. Insiders sold a total of 5,442 shares of company stock worth $247,577 over the last three months. Corporate insiders own 0.58% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on CTLT. Royal Bank of Canada lifted their target price on Catalent from $51.00 to $58.00 and gave the stock an “outperform” rating in a report on Wednesday. Barclays lifted their target price on shares of Catalent from $35.00 to $42.00 in a report on Monday, June 12th. JPMorgan Chase & Co. downgraded shares of Catalent from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $90.00 to $45.00 in a research report on Sunday, May 21st. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Catalent from $37.00 to $45.00 and gave the stock a “hold” rating in a research report on Tuesday, August 15th. Finally, Bank of America lifted their target price on shares of Catalent from $39.00 to $46.00 in a research report on Thursday. Two analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Catalent has an average rating of “Hold” and an average target price of $59.42.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.